# Oaktree Acquisition Corp. III Life Sciences > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Oaktree Acquisition Corp. III Life Sciences). ## Overview Oaktree Acquisition Corp. III Life Sciences is a U.S.-based special purpose acquisition company formed to identify and combine with a business in the life sciences sector. As a blank-check company, it does not operate a commercial product business itself; instead, it holds IPO proceeds in trust while searching for a target acquisition. ## Products & services • Special purpose acquisition company (SPAC) structure • Public shares and warrants • Trust account capital for a future business combination • Sponsor-backed acquisition vehicle - **SPAC vehicle** (100%) — Capital-raising shell company formed to complete a future business combination. - Special purpose acquisition company (SPAC) structure - Public shares and warrants - Trust account capital for a future business combination - Sponsor-backed acquisition vehicle ## Customers The company does not sell products or services to end customers in the ordinary course. Its economic counterparties are public shareholders, warrant holders, the sponsor, underwriters, and ultimately a future merger target in the life sciences sector. - **Public shareholders** (primary) — Invest in the SPAC units and shares for exposure to a future acquisition transaction. - **Sponsor and affiliates** (primary) — Provide private placement capital, administrative services, and transaction support. - **Future acquisition target** (primary) — A life sciences company that may merge with the SPAC to access public markets. - **Underwriters** (secondary) — Facilitate the IPO and earn underwriting fees tied to the capital raise. - Public investors buying units, shares, and warrants - Sponsor providing seed capital and administrative support - Underwriters involved in the IPO process - Future life sciences target company in a business combination ## Geography The company is incorporated and headquartered in the United States, and its securities are issued through U.S. capital markets. Its operating footprint is currently limited to the U.S. while it searches for a target, though a future business combination could introduce international exposure depending on the acquisition. - United States is the corporate and capital-markets base - No operating revenue geography is disclosed because it has no operations - Future geography will depend on the acquired life sciences business - Current activity is centered on U.S. listing and trust-account management ## Strategy The company’s strategy is to identify and complete a business combination with a life sciences target within its permitted timeframe. It also manages the trust account, sponsor support arrangements, and public-company compliance while preserving optionality for a transaction. - **Complete a business combination** (short-term) — The SPAC has no operating business until it merges with a target. - **Manage liquidity and working capital** (short-term) — Public-company and transaction costs continue before any merger closes. - **Preserve shareholder value through structure** (medium-term) — Redemptions and trust-account mechanics affect the capital available for a deal. - Find and negotiate a life sciences business combination - Maintain trust-account capital until a transaction closes - Use sponsor and officer support for working capital needs - Preserve flexibility to extend the combination period if needed ## Risks The main risk is that the company may fail to complete a business combination before its deadline, which could force liquidation. It also faces financing, redemption, and execution risks typical of SPACs, along with accounting complexity around warrants and redeemable shares. - **Business combination deadline risk** [critical] — If no transaction closes by the deadline, the company may liquidate and dissolve. - **Redemption risk** [high] — Shareholder redemptions can materially reduce cash available for an acquisition. - **Financing risk** [high] — The company may need sponsor or third-party funding to meet working capital needs. - **Transaction execution risk** [high] — A target may not be found, negotiated, approved, or closed on acceptable terms. - **Accounting and valuation risk** [medium] — Warrants and redeemable shares require fair-value and classification judgments. - Failure to complete a business combination could trigger liquidation - Redemptions can reduce trust-account capital available for a deal - Additional financing may not be available on acceptable terms - Warrant and redeemable-share accounting requires judgment - Public-company and transaction costs continue without operating revenue ## Accounting The most important accounting issues are the classification and valuation of warrants and redeemable Class A shares, both of which can materially affect equity and liabilities. Because the company has no operating revenue, reported results are driven mainly by interest income on trust assets, public-company costs, and transaction-related expenses. - **Warrant instruments** — Can change reported equity, liabilities, and earnings volatility - **Class A redeemable share classification** — Affects balance sheet structure and shareholder equity - **Trust account interest income** — Drives reported net income despite no operating business - **Going-concern assessment** — Can influence disclosure and liquidity presentation - Warrant classification affects whether instruments sit in equity or liabilities - Redeemable Class A shares require careful presentation and measurement - Interest income on trust assets is the main source of non-operating income - Public-company and due-diligence costs drive period-to-period results - Going-concern assessment depends on financing and deal completion --- *Last updated: 2026-04-29T04:43:29.256146+00:00*